Arena Pharmaceuticals to Host R&D Day on October 4 in New York City

SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds: etrasimod in inflammatory bowel disease (IBD), ralinepag in pulmonary arterial hypertension (PAH), and olorinab in visceral pain. The Company will also provide updates on its broader portfolio. The event will take place in New York City on Thursday, October 4, 2018, from 8-11:00 a.m. EDT.

The meeting will feature leading international experts William J. Sandborn, MD, Professor of Medicine, Adjunct Professor of Surgery and Chief, Division of Gastroenterology and Vice Chair for Clinical Operations at the Department of Medicine at the University of California, San Diego and UC San Diego Health System; and Victor F. Tapson, MD, FCCP, FRCP, Director of the Venous Thromboembolism and Pulmonary Vascular Disease Research Program, Director of Clinical Research at the Women's Guild Lung Institute, and Associate Director of Pulmonary and Critical Care Medicine at Cedars – Sinai. Drs. Sandborn and Tapson will discuss the current disease landscapes and how the Arena compounds may be utilized within the treatment paradigms. Both experts will be available to answer questions during the event.

William J. Sandborn, MD
William Sandborn, MD, is a board-certified gastroenterologist who is one of the world's top experts in the management of ulcerative colitis and Crohn's disease. He directs the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health. In addition, he is chief of the Division of Gastroenterology, vice chair of clinical operations for the Department of Medicine, and a member of the Clinical Practice Oversight (CPO) Board for UC San Diego Health. A professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators. With his physician collaborators, he evaluates and develops new diagnostic modalities and medical therapies for IBD. Dr. Sandborn is internationally recognized for his contributions in the fields of biotechnology therapy, clinical pharmacology, conduct of clinical trials, diagnostic and treatment of pouchitis, epidemiology and natural history, and endoscopic and radiographic imaging techniques. His clinical trials have been instrumental to developing modern treatments for IBD. Dr. Sandborn has published nearly 600 articles in prestigious journals, including the New England Journal of Medicine, The Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn. Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine. He is board-certified in gastroenterology.

Victor F. Tapson, MD
Victor F Tapson, MD, FCCP, FRCP, is Professor of Medicine, Director of Clinical Research for the Women's Guild Lung Institute, Director of the Venous Thromboembolism and Pulmonary Vascular Disease Research Program, and Associate Director of the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center in Los Angeles, CA. He earned his medical degree from Drexel University School of Medicine in Philadelphia, PA. He completed his internship and residency in internal medicine at Duke University Medical Center, where he went on to become Chief Resident. In addition, he completed a fellowship in Pulmonary and Critical Care Medicine at Boston City Hospital in affiliation with Boston University. After his fellowship, he co-founded the Duke Lung Transplant program as well as starting the Duke Pulmonary Vascular Disease Center, where he served as Director for the next 20 years. Dr Tapson has devoted his medical career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism. He has authored more than 200 peer-reviewed manuscripts and has edited numerous books and book chapters. In addition, he was involved with the development of the American Thoracic Society's clinical practice guidelines for the diagnosis of venous thromboembolism as well as the international guidelines for the selection of lung transplant candidates.

Drs. Sandborn and Tapson are consultants to Arena.

Attendance at the event is intended for institutional investors, sell-side analysts, investment bankers and business development professionals.  A live and archived webcast of the event, with slides, will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.

About Arena Pharmaceuticals
Arena Pharmaceuticals is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. The most advanced investigational clinical programs are ralinepag (APD811), in a Phase 3 program for pulmonary arterial hypertension (PAH), and etrasimod (APD334), expected to commence a Phase 3 program for ulcerative colitis (UC) and a program in Crohn's disease (CD), and which has potential utility for a broad range of immune and inflammatory conditions. Arena is also evaluating olorinab (APD371) in a Phase 2 study for the treatment of visceral pain associated with Crohn's disease, as well as other drug candidates in earlier research and development stages.

In addition, Arena has several collaborations, including with Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ^® - marketed product).

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "will," "potentially," "may," "focused on," "expected," "potential," or words of similar meaning, or they may be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about the upcoming R&D Day, the potential of Arena's investigational compounds, and Arena's focus, goals, strategy, clinical programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include that clinical programs may not proceed at the time or in the manner expected or at all, as well as those factors disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, which was filed with the SEC on August 7, 2018. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Corporate Contact:                                      
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer                                  
[email protected]
858.210.3636

Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
646.627.8384

SOURCE Arena Pharmaceuticals, Inc.

Related Links

http://www.arenapharm.com